Notícias

RapAdmin

Imeglimin
Imeglimin2752×1536 393 KB

Sarcopenia, the age-related loss of muscle mass and strength, has no approved drug treatment anywhere in the world. This study reports that imeglimin, a first-in-class oral antidiabetic already licensed in Japan under the name Twymeeg, preserved skeletal muscle in two independent mouse models of muscle loss. In obese mice, six weeks of treatment restored shrunken fast-twitch fibres in the extensor digitorum longus to the size seen in lean animals, a 66 percent increase over untreated obese controls. In naturally aged mice, twelve weeks of treatment produced a 14 percent increase in fast-twitch fibre size and, more importantly, a roughly 15 percent gain in grip strength measured in a separate cohort. The drug acted selectively on Type IIX/D glycolytic fibres, the same fibre population that is preferentially lost in human sarcopenia. Exploratory bone imaging suggested parallel protection against age-related bone loss. The work was funded by Sumitomo Pharma, which markets the drug.

Muscle loss with age is not a cosmetic problem. Sarcopenia predicts falls, fractures, hospitalisation, loss of independence, and death, and it affects a substantial fraction of adults over seventy. Despite decades of work there is still no approved pharmacological treatment. Resistance training and adequate protein remain the only interventions with solid evidence, and both require sustained effort that many older adults cannot manage.

Against that background, a Japanese and Chinese research team has reported that an existing drug preserves muscle in mice. Imeglimin is a glimin, a new chemical class of oral diabetes medication approved in Japan. It is a structural relative of metformin, but its primary action is on mitochondria, improving respiratory chain function and reducing the reactive oxygen species that mitochondria leak when a cell is under metabolic stress.

The team tested it in two separate models of muscle loss and it worked in both. Obese mice on a high-fat diet lost roughly a third of the cross-sectional area of their fast-twitch fibres. Adding imeglimin to their food restored those fibres to lean-animal dimensions. In naturally aged mice, eighteen months old at the start, twelve weeks of treatment produced a smaller but real increase in fibre size.

The result that matters most is the functional one. In a separate cohort of aged animals, grip strength after seven weeks of treatment was about 15 percent higher than in untreated age-matched controls. Morphology is suggestive; strength is the endpoint that maps onto what sarcopenia actually costs people.

Two features sharpen the case. First, the effect was fibre-type selective, hitting Type IIX/D glycolytic fibres while leaving slow-twitch soleus fibres largely alone. That is precisely the pattern of human sarcopenia, where Type II fibres are preferentially lost. Second, the drug produced these effects in aged mice without changing body weight, fasting insulin, or glucose tolerance at all. That dissociation matters because it argues the muscle effect is direct rather than a downstream consequence of better metabolic control, which is what a repurposing candidate would need to show.

RNA sequencing pointed at the mechanism: a coordinated shutdown of stress-response and inflammatory gene programmes inside the muscle fibres themselves. Notably, the classical muscle-wasting machinery was untouched.

The context is favourable. Most current metabolic drugs, including GLP-1 agonists and SGLT-2 inhibitors, are associated with lean mass loss. A metabolic drug that protects muscle would occupy distinct ground. This remains a mouse study in male animals only, with a small headline experiment and no human muscle data.

Actionable Insights

Anchor on the right number. The 66 percent fibre-size gain in obese mice came from only five animals per group, which means the true effect could be anywhere from modest to enormous. The aged-mouse experiment used ten to twelve animals and produced a 14 percent fibre-size gain and roughly a 15 percent grip strength gain, about 8 grams on a baseline of 53. In statistical terms that strength effect is large, somewhere near a standardised effect size of 1.0 to 1.3, but small studies inflate such numbers. For scale, a 15 percent strength improvement is comparable to what a few months of resistance training delivers in older adults.

Imeglimin, currently approved only in Japan (but it is available inexpensively in India, including from many online pharmacies who sell to international buyers), and it may eventually offer a viable approach to minimizing muscle loss while aging. Watch for a dedicated human sarcopenia trial. None has yet been reported. Many people here on our forums have already started using Imeglimin as its helpful with keeping blood sugar spikes low, helps keep A1C levels down, and avoids the muscle-related problems of Metformin (in fact helps muscles, it now seems).

Context and Source

  • Open Access Paper: Imeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing
  • Institutions: Japan Institute for Health Security (Diabetes Research Center and Department of Laboratory Animal Medicine), Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Japan; Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China
  • Countries: Japan (lead) and China
  • Journal: Journal of Cachexia, Sarcopenia and Muscle (Wiley), 2026.
    Impact evaluation: The impact score of this journal is 9.1 (2024 Journal Impact Factor; sources reporting the 2025 release list 9.9), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

Screenshot 2026-08-26 at 1.58.37 PM
Screenshot 2026-08-26 at 1.58.37 PM1942×976 139 KB

NeuroAge Therapeutics has announced Younger 2027, a structured, six-month biological aging competition designed to evaluate multi-modal longevity and healthspan interventions across human participants. With baseline diagnostics shipping in late 2026 ahead of an in-person kickoff on January 11–12, 2027, at Fort Mason in San Francisco, the initiative evaluates whether self-directed lifestyle, nutritional, or therapeutic protocols can measurably reverse biological age before final testing closes in August 2027.

Rather than relying on a single surrogate endpoint, the competition tracks biological aging across multiple distinct physiological domains:

  • Epigenetics & Systemic Biomarkers: TruDiagnostic’s DNA methylation suite, incorporating DunedinPACE pace-of-aging metrics, SymphonyAge 11-organ system clocks, and clinical blood biomarker panels.
  • Neurocognitive Metrics: NeuroAge’s mobile-administered NeuroGames cognitive battery, quantifying processing speed, memory, and executive function.
  • Facial Senescence: FaceAge, a deep-learning vision algorithm developed at the Harvard AIM Lab that infers biological age and mortality hazard from standardized facial photography.
  • Functional Diagnostics: Cardiorespiratory fitness (VO2​ max via wearable integration), grip dynamometry, and neuromuscular capacity.

A high-tier “Ultra” cohort adds serial non-contrast brain MRIs with volumetric analysis, GlycanAge IgG glycan inflammatory profiling, RNA-based transcriptomic neuroinflammation assays, and access to pre-release proteomic and epigenetic clocks developed at Yale University and Stanford-affiliated Vero Bioscience.

This week is the last week for early bird pricing for the Younger Biological Age Contest. You can submit your baseline Sep 1- Feb 1 for a rolling 6 month window. Find out more/register here:

RapAdmin

MultiO
MultiO2752×1536 273 KB

This placebo-controlled, balanced cross-over clinical trial involving 10 healthy males demonstrates that acute pharmacological manipulation of prolactin levels directly impacts sexual drive, arousal, and the post-orgasmic recovery period. Using 0.5 mg of the dopamine D2 agonist cabergoline to suppress prolactin significantly enhanced sexual function and drive, while 50 micrograms of protirelin induced hyperprolactinemia and blunted these parameters, establishing prolactin as a key neuroendocrine modulator of human sexual behavior and central dopaminergic tone.

The neuroendocrine mechanisms governing human sexual satiety and the post-coital refractory period have long been observationally linked to prolactin, a hormone that surges following orgasm. While chronic hyperprolactinemia is clinically recognized for its libido-suppressing effects, the acute role of prolactin in real-time sexual behavior remained poorly defined. This investigation isolated the prolactin variable by pharmacologically driving it to physiological extremes during controlled sexual stimulation.

By administering cabergoline, researchers suppressed the natural post-orgasmic prolactin spike, keeping levels at a baseline of approximately 2.5 ng/ml. This intervention removed the neuroendocrine braking mechanism, resulting in amplified subjective sexual drive, heightened consummatory arousal, and an enhanced capacity to reinitiate sexual activity. Conversely, driving prolactin levels artificially high via intravenous protirelin prior to orgasm prolonged ejaculation latency and trended toward suppressing overall sexual appetite. Notably, the concurrent administration of both drugs neutralized the sexual enhancements seen with cabergoline alone, strongly suggesting that the observed aphrodisiac effects are not merely an artifact of systemic dopamine agonism, but are specifically mediated through the suppression of prolactin.

For the fields of neuroendocrinology and longevity, these findings validate a specific negative feedback loop. Post-orgasmic prolactin likely acts on the central nervous system to suppress dopaminergic signaling in the nigrostriatal and mesolimbocortical pathways. Preserving dopaminergic sensitivity is a primary objective in mitigating neurocognitive aging. Demonstrating that acute neuroendocrine responses can be bypassed pharmacologically opens the door to targeted interventions for age-related sexual dysfunction and neuroendocrine decline.

Actionable Insights: For individuals optimizing sexual health and vitality, the primary takeaway is the inverse relationship between prolactin and dopaminergic sexual drive. The administration of a low-dose dopamine D2 agonist (0.5 mg cabergoline) is highly effective at preventing the post-orgasmic prolactin surge, thereby reducing post-coital fatigue and accelerating the recovery of sexual appetite.

To quantify the real-world magnitude of this intervention, we extract the effect sizes directly from the trial data. Under the cabergoline protocol, subjective scoring of the “Appetitive Phase” (sexual drive) increased by roughly 50 percent relative to the placebo baseline. Furthermore, artificially raising prolactin increased ejaculation latency by approximately 66 percent (from 4.5 minutes to 7.5 minutes). The standardized effect size for cabergoline on sexual drive enhancement is exceptionally large. Given the crossover design and reported significance (p < 0.05) within a 10-subject cohort, the estimated Cohen’s d exceeds 0.8. This translates to a highly noticeable, practical improvement in subjective libido and a marked reduction in the physical and psychological latency of the refractory period.

Context/Source:

Leitura Relacionada:

RapAdmin

FitnessMortalityBenefits
FitnessMortalityBenefits2752×1536 418 KB

A nationwide cohort study of 13,423 older adults demonstrates that objectively measured physical fitness is an independent predictor of all-cause mortality, outperforming conventional disease-focused risk stratification. Over a median seven-year follow-up, high performance in dynamic agility, single-leg balance, and lower-body strength reduced the risk of death by 45% to 59%, while a composite multi-domain fitness score reduced mortality risk by 61%.

Standard geriatric medicine evaluates mortality risk by cataloging chronic diseases, laboratory abnormalities, and deficit indices. This study shifts the paradigm toward physiological reserve, evaluating what an individual’s neuromuscular and cardiopulmonary systems can functionally execute. Researchers linked Taiwan’s National Physical Fitness Survey Database with the mandatory single-payer National Health Insurance Research Database to track 13,423 community-dwelling adults aged 65 and older over a median follow-up of 7.0 years. During this timeframe, 1,631 participants died.

Participants underwent seven standardized physical assessments evaluating cardiorespiratory endurance, upper-body strength, lower-body strength, flexibility, dynamic agility, and static balance. The findings demonstrate that functional performance robustly predicts survival even after extensive adjustment for age, sex, socioeconomic status, baseline body mass index, ten major chronic medical conditions, and self-reported physical activity.

The strongest individual survival advantages belonged to dynamic agility and balance. Older adults in the top 20% of the 8-foot up-and-go test and the one-leg balance test experienced less than half the mortality rate of those in the lowest 20%. Combining all assessments into an aggregate composite fitness index yielded the steepest gradient, cutting the overall hazard of death by 61%.

The dose-response analysis uncovered critical non-linear dynamics. Survival gains did not advance indefinitely across all domains. For flexibility, such as reaching behind the shoulder blades, mortality risk plummeted when moving out of extreme stiffness but plateaued entirely past a baseline threshold of functional reach. Lower-body power exhibited similar saturation beyond 15 repetitions on the 30-second chair stand test.

These findings indicate that longevity interventions should prioritize motor coordination, neuromuscular integrity, and functional power over extreme flexibility or isolated diagnostic checklists.

Actionable Insights

For clinicians and health-conscious adults, this study provides clear physical benchmarks that translate directly into survival advantages.

  • Prioritize Lower-Body Power: Participants in the top tier of the 30-second chair stand test reduced their mortality risk by 45% (Adjusted Hazard Ratio [AHR] = 0.55; 95% CI, 0.46-0.65) compared to the lowest performers. In absolute terms, death rates dropped from 3.62 to 1.03 deaths per 100 person-years. Aim for at least 15 unassisted chair stands in 30 seconds.

  • Train Balance and Neuromuscular Agility: The highest performers in dynamic agility (8-foot up-and-go) achieved a 59% reduction in death rate (AHR = 0.41; 95% CI, 0.33-0.51; 0.72 vs 4.07 deaths per 100 person-years). Superior static balance (one-leg stance) cut mortality risk by 50% (AHR = 0.50; 95% CI, 0.42-0.59). Target an 8-foot rise-walk-sit time under 7 seconds and a single-leg stance of 15 to 30 seconds.

  • Maintain Moderate Aerobic Endurance: Cardiorespiratory fitness (2-minute step test) showed a 42% risk reduction (AHR = 0.58; 95% CI, 0.49-0.68).

  • Avoid Over-Investing in Flexibility: Extreme stiffness increases mortality risk, but flexibility gains past a basic functional range provide no additional survival dividend. Once basic range of motion is achieved, dedicate training volume to resistance, power, and balance.

Context and Source

  • Open Access Paper: Physical Fitness and All-Cause Mortality in Older Adults
  • Institutions: National Yang Ming Chiao Tung University, National Taiwan University of Sport, Chung Yuan Christian University, Fu Jen Catholic University, National Sun Yat-sen University, National Taiwan Normal University, Ton Duc Thang University, Chung Shan Medical University
  • Country: Taiwan
  • Journal Name: JAMA Network Open
  • Impact Evaluation: The impact score of this journal is 11.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a High impact journal.

RapAdmin

YoungBloodIGF1BBB
YoungBloodIGF1BBB2752×1536 455 KB

Researchers at the University of Oklahoma Health Sciences Center and Semmelweis University surgically joined the circulations of old and young mice (heterochronic parabiosis) and used live two-photon imaging through cranial windows to watch the aged brain’s blood vessels repair themselves. Old mice sharing blood with young partners showed markedly less leakage across the blood-brain barrier and roughly double the density of brain capillaries. The team then broke the insulin-like growth factor 1 (IGF-1) axis in two independent ways: deleting the IGF-1 receptor specifically from the aged mouse’s own blood vessel lining, or knocking down IGF-1 production in the young partner’s liver. Either manipulation largely abolished the benefit. The conclusion is that young blood does not rejuvenate brain vasculature by some generic mechanism; it requires a working IGF-1 ligand on one side and a working IGF-1 receptor on the endothelium on the other. The effect was attenuated but not fully erased, so other circulating factors are also in play.

For a decade, heterochronic parabiosis has been longevity biology’s most theatrical experiment: stitch an old mouse to a young one, share a bloodstream, and watch old tissues behave younger. The recurring criticism has been that it is a black box. Something in young blood helps. Nobody could say what, or through which door it enters the cell.

This study opens one of those doors. The team focused on the brain’s microvasculature, which is an underappreciated driver of cognitive aging. As we age, the capillary network thins out (rarefaction) and the blood-brain barrier becomes leaky, letting blood proteins into brain tissue where they inflame microglia, strip synapses, and damage white matter. This is a plausible engine of vascular cognitive impairment and a contributor to Alzheimer’s pathology.

The candidate mediator was IGF-1, the growth hormone-driven factor that falls steeply with age in a decline called somatopause. IGF-1 supports the endothelium: nitric oxide production, mitochondrial function, tight-junction maintenance, and new vessel growth.

Rather than infusing IGF-1, the researchers subtracted it, using two genetic tools that attack the axis from opposite ends. In one group, aged mice lacked the IGF-1 receptor on their endothelial cells, so young blood arrived but the vessel wall could not respond. In another, young partners had IGF-1 production silenced in the liver, so the blood arriving was IGF-1-poor. Both manipulations blunted the rejuvenation.

The pattern in the leakage data is telling. The effect was clearest for the smallest tracer molecule, a 3 kilodalton dextran, the most sensitive probe of subtle barrier defects. There the loss of benefit was dramatic: aged mice with broken IGF-1 signaling leaked more than aged mice that had never seen young blood at all.

The honest headline is not only that IGF-1 is the rejuvenation factor. It is that IGF-1 receptor signaling is a required conduit through which much of the benefit passes. That matters because it is tractable in a way “young plasma” never was: receptor pathways have downstream nodes that can be drugged, and IGF-1 sensitivity is modifiable by exercise and metabolic health. It also sits awkwardly beside decades of work showing that reduced IGF-1 signaling extends lifespan in worms, flies, and mice, which sets up a genuine tissue-specific conflict the field will have to resolve. Something that lengthens life in aggregate may still starve the brain’s capillary bed of the growth signal it needs to maintain itself.

The caveats are significant. Sample sizes were five to eight animals per group, the comparison groups came from a previously published cohort rather than being run alongside, and several of the supporting statistics sit just outside conventional significance. No cognition was tested.

Actionable Insights

This is mouse surgery with genetic knockouts, and no human intervention is embedded in it. What it changes is which way to lean on a contested question.

The take-home is that IGF-1 is not uniformly bad when it comes to aging. Longevity culture absorbed the idea that low IGF-1 equals long life, largely from worm and dwarf-mouse genetics. This study is evidence that the brain’s blood vessels want the opposite. When IGF-1 signaling was removed, the capillary density benefit was almost entirely lost, and barrier leak to the smallest tracer got worse than in untreated old animals.

The magnitudes are large, in mice. Using conservative estimates back-calculated from the paper’s own statistics, young blood raised capillary density with a standardized effect size near d = 1.7. For scale, 0.2 is small, 0.5 moderate, 0.8 large, and 1.7 means the average treated mouse sits above roughly 95 percent of untreated ones. Blocking IGF-1 signaling erased 70 to 82 percent of that gain. Barrier leak effects ran d = 1.0 to 2.7.

The practical translation is indirect: do not chase IGF-1 suppression as a blanket longevity strategy, and favor what preserves IGF-1 responsiveness in tissue, meaning resistance and aerobic training, adequate protein and sleep, and insulin sensitivity. The authors explicitly warn against ongoing exogenous IGF-1 (or GH) supplementation due to possible cancer risks. People are exploring pulsatile strategies to balance risks and potential rewards.

Context and Source

Leitura Relacionada:

RapAdmin

SupercentenarianTCells
SupercentenarianTCells2752×1536 405 KB

Japanese researchers profiled individual T cells from 28 people spanning their 70s to beyond 110, and found that a rare and unusual immune cell, the CD4 cytotoxic T lymphocyte (CD4 CTL), becomes dramatically more common right around the age of 100. These cells are helper T cells that have retrained themselves as killers. In supercentenarians they made up a median of 17.6 percent of all T cells, against 4.0 percent in the 70s-to-90s group. They are dominated by enormous single clones, averaging a third of the entire CD4 CTL pool in one person, which implies decades of repeated stimulation by the same handful of persistent targets. Critically, these cells showed no molecular signs of exhaustion, and the receptor sequences of the biggest clones matched sequences previously catalogued in lung cancer tumors. The authors propose that CD4 CTL expansion is an adaptive rewiring of the aged immune system toward a small set of stubborn antigens, possibly including precancerous and senescent cells.

The oldest people on Earth are not simply people who avoided disease. Their immune systems appear to have reorganized themselves into something structurally different, and a new study puts a number on how different.

Working with blood from 28 Japanese donors, including ten supercentenarians aged over 110, a team from the University of Osaka, RIKEN and Keio University sequenced the transcriptome, the surface proteins and the antigen receptor of 43,584 individual T cells. They were following up their own earlier discovery that supercentenarians carry unusual numbers of CD4 cytotoxic T lymphocytes.

Textbook immunology divides T cells cleanly. CD4 cells are helpers, coordinating the response. CD8 cells are killers, destroying infected and malignant cells. CD4 CTLs break that rule. They are helper-lineage cells that have acquired the killing machinery, and in most adults they are a rounding error, under 5 percent of T cells.

The new data show these cells climbing steadily with age, then rising sharply somewhere around the century mark. The team also built a machine learning classifier and applied it to more than five million cells from 1,512 published samples covering ages 0 to 110-plus, which reproduced the same late-life inflection.

The more revealing finding is what the cells’ receptors look like. In each supercentenarian, the CD4 CTL pool was not a diverse army. It was a few gigantic clones, one of them accounting for 54 percent of that person’s entire CD4 CTL population. Clones that large do not arise by accident. They are the signature of an antigen that keeps showing up, year after year, for decades.

Yet the cells did not look worn out. Exhaustion markers such as PD-1, TIGIT and LAG3 stayed low. And when the researchers searched the receptor sequences against a database of 690 million sequences from nearly 20,000 people, the top clones matched sequences found in tumors, most often non-small-cell lung cancer, even though none of these centenarians had any cancer history.

The authors’ interpretation, offered cautiously, is that living past 100 involves a deliberate narrowing of immune attention. Broad surveillance gives way to a standing garrison aimed at a few persistent threats: latent viruses, senescent cells, and possibly the earliest precancerous lesions that never got to become tumors. That is a story worth telling. It is not yet a proven one.

Insights

There is no intervention in this paper. Read it as a description of what extreme longevity looks like from the inside, not as instructions.

What can honestly be extracted:

The magnitude is real but modest in statistical terms. Median CD4 CTL share was 4.0 percent in the 70s-to-90s group, 9.6 percent in centenarians, 17.6 percent in supercentenarians. That is a 4.4-fold difference between the youngest and oldest groups, or 13.6 percentage points in absolute terms. Converting the reported trend statistic into a standardized effect size gives roughly Cohen’s d of 0.9, conventionally called a large effect. But with only 28 people total, and eight in the youngest group, that estimate carries wide uncertainty and is very likely inflated. Individual variation was enormous: one healthy 100-year-old assigned to the youngest comparison group had the highest CD4 CTL fraction of anyone in the study.

If a highly differentiated, clonally expanded, cytotoxic T cell population is a feature of the healthiest extreme survivors, then longevity strategies built on broadly damping immune activation deserve more scrutiny than they usually get. Not every inflammatory-looking immune signature in an old person is damage. Some of it may be the surveillance that kept them alive.

There is currently no clinical test for CD4 CTL fraction, and no evidence that raising it would help anyone. [Confidence: High]

Context and Source

  • Open Access Paper: CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging
  • Authors: Hashimoto K, Kojima-Ishiyama M, Inokuchi H, Tagami M, Sasaki T, Mizuguchi K, Okazaki Y, Taniuchi I, Ishigaki K, Hirose N, Carninci P, Arai Y
  • Institutions: Institute for Protein Research, The University of Osaka; RIKEN Center for Integrative Medical Sciences, Yokohama; Keio University School of Medicine, Tokyo (Department of Microbiology and Immunology, and Centre for Supercentenarian Medical Research); Human Technopole, Milan, Italy.
  • Countries: Japan (primary), with an Italian collaborating institution.
  • Journal: Cell Reports (Cell Press / Elsevier). Article 117728, 2026.
  • Impact evaluation: The impact score of this journal is 7.7 (most recent Journal Impact Factor; the journal has drifted down from a 2021 peak near 10.0), evaluated against a typical high-end range of 0 to 60-plus for top general science journals, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

HQNyAzFbcAAkxhZ
HQNyAzFbcAAkxhZ1536×1024 284 KB

Researchers at Xuanwu Hospital, Capital Medical University screened 118 environmental, lifestyle, early-life, psychosocial and socioeconomic exposures against biological-age acceleration in 236,099 UK Biobank participants, then repeated the analysis separately in men and women. Lifestyle dominated every other domain by a wide margin. Women showed a slightly stronger response to the same adverse lifestyle exposures than men, but men carried a far larger preventable burden at the population level simply because more of them live badly (73% of men versus 56% of women in the intermediate or unfavourable lifestyle tertiles). Roughly a quarter of accelerated-aging cases in the whole cohort were attributable to the five modifiable domains combined. Reproductive variables including menopause, early menarche and stillbirth added independent, though modest, risk in women.

Aging is not a single process running at a single speed. Two people born the same year can be biologically a decade apart, and researchers now routinely quantify that gap using blood-based “clocks” that estimate biological age from ordinary lab values. The question this paper asks is deceptively simple: what actually drives the gap, and does it work the same way in men and women?

The team ran what is essentially a hypothesis-free sweep. Rather than picking a favourite exposure and testing it, they threw 118 candidate factors at the data at once, an approach borrowed from genomics called an exposure-wide association study. Everything went in: air pollution, greenspace, mobile-phone use, television hours, sleep, supplements, salt at the table, sunscreen habits, loneliness, income, employment, childhood adversity, and for women, menstrual and reproductive history.

The result is a clean hierarchy. Lifestyle beat everything. People in the worst lifestyle tertile had roughly two and a half times the odds of being classified as biologically accelerated compared with the best tertile. Socioeconomic status came second, psychosocial factors third, early-life factors fourth. Environmental exposures, the domain that gets the loudest press coverage, contributed almost nothing once everything else was accounted for.

The big idea, though, is the sex split. Women appeared more sensitive to the same bad habits: the odds ratio for an unfavourable lifestyle was 2.88 in women versus 2.37 in men, even though similar proportions were exposed. But when the authors asked a different question, how much accelerated aging could be erased if everyone moved to a favourable profile, the answer flipped. Men had 41.7% of cases theoretically preventable; women only 15.0%. The reason is not biology but arithmetic: more men are exposed in the first place.

There is a caveat the paper handles too gently. The two clocks contradict each other. On one measure women look 17 years older than men on average; on the other, men look slightly older. Since both measures were calculated by comparing everyone against the pooled average of the whole cohort, one sex is forced above the line and the other below it by construction. What the data show robustly is that lifestyle matters enormously and that men have more room to improve. What they do not show, yet, is that women’s biology ages faster.

Actionable Insights

The practical content here is unglamorous and consistent. Effect sizes below are standardised so they can be compared with each other. Cohen’s d of 0.2 is small, 0.5 moderate, 0.8 large.

Diet was the single strongest protective factor found. The best diet score versus the worst carried d = 0.76 in women and d = 0.60 in men, translating to a biological age roughly 3.0 years younger on the phenotypic clock and 7.7 years younger on the physiological clock. That is the largest modifiable signal in the entire 118-factor screen.

Television time was the strongest behavioural risk factor in women: three or more hours daily was associated with d = 0.42, about 1.7 years of added phenotypic age.

Habitually adding salt at the table carried d = 0.32 overall and d = 0.38 in men, an unusually large effect for such a small habit.

Routine sun and UV protection was protective at d = 0.25.

Overall, moving from the worst to the best lifestyle profile corresponds to d = 0.51, which in plain terms is roughly a 15 percentage-point absolute drop in the chance of being classified as an accelerated ager.

Caution: this is cross-sectional observational data. These are associations, not demonstrated causes.

Context and Source

  • Open Access Paper: Sex differences in aging acceleration: higher susceptibility in women, greater preventability in men
  • Authors: Ziye Ren, Shuiyue Quan, Fangyu Li, Longfei Jia
  • Institution: Department of Neurology and Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University; National Clinical Research Center for Geriatric Diseases, Beijing, China
  • Country: China (data source: UK Biobank, United Kingdom)
  • Journal: npj Aging (Nature Portfolio, published in partnership with the Japanese Society of Anti-Aging Medicine), published online 20 August 2026.
  • Funding: Brain Science and Brain-like Intelligence Technology National Science and Technology Major Project, National Natural Science Foundation of China, Beijing Hospitals Authority, Xuanwu Hospital. No competing interests declared.
    Journal impact: The impact score of this journal is 13.0 (2025 Journal Impact Factor; 5-year JIF 12.2), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

HeatRisks
HeatRisks2752×1536 452 KB

A Stanford, Penn State, Purdue and Nebraska team combined laboratory-derived human heat tolerance limits for three adult age bands with 14 climate models and gridded, age-stratified population projections to ask a question nobody had properly asked: what happens to global heat risk estimates when you stop assuming everyone thermoregulates like a 25-year-old? The answer is that the risk picture gets dramatically worse. Older adults face more frequent and more geographically widespread uncompensable heat stress at 1.5 degrees C of warming than young adults do at 4 degrees C. Using age-appropriate thresholds instead of young-adult thresholds multiplies the estimated globally exposed population by a factor of 8.2 at 1.5 degrees C. Under 3 degrees C, roughly 2 billion people, including 1.3 billion adults over 60, would experience at least 180 hours per year of conditions in which the human body cannot shed heat fast enough to hold core temperature steady.

There is a temperature and humidity combination beyond which the human body simply loses. Sweat cannot evaporate fast enough, blood cannot be pushed to the skin fast enough, and core temperature starts climbing and does not stop. Physiologists call this the point of uncompensable heat stress. For a fit young adult in a climate chamber, that point sits near a wet-bulb temperature of about 30.6 degrees C in humid conditions, well below the 35 degrees C figure that dominated climate reporting for a decade.

The new work in The Lancet Planetary Health does something more uncomfortable. It takes the fact that thermoregulation is an aging phenotype and puts a number on it at planetary scale.

Sweat gland output falls with age. The skin’s ability to dilate its blood vessels falls with age. Maximum cardiac output and chronotropic reserve fall with age. The result is that an older adult reaches the uncompensable point in conditions a young adult tolerates comfortably. Previous global projections ignored this entirely, applying young-adult limits to grandparents.

Correcting that assumption changes everything. The headline finding is a direct trade-off between biology and physics: the physiological penalty of being over 60 is worth roughly 2.5 degrees C of global warming. Older adults living in a 1.5 degrees C world are in more thermal trouble than young adults living in a 4 degrees C world. Aging is, on this metric, a more powerful risk multiplier than the entire remaining span of plausible twenty-first century warming.

The geography is brutally specific. The Indo-Gangetic Plain, the Persian Gulf coast, eastern China, west Africa and southeast Asia dominate. In Delhi, Lahore and Dubai, older adults would accumulate close to or more than 1000 hours per year of uncompensable heat even at 1.5 degrees C. Push past 3 degrees C and those cities deliver sustained day and night exposure for three consecutive months, coinciding with the Kharif cropping season that feeds more than half a billion people. Bangkok reaches 3840 hours per year at 4 degrees C, which is 44 percent of the calendar.

Thirteen countries combine poverty rates above 50 percent with mass older-adult exposure. India, Pakistan, Bangladesh, Myanmar and Niger appear on every list. Each additional degree of warming adds roughly one billion people to the exposed population.

Actionable Insights

What the paper demonstrates is an exposure gradient, not a treatment effect. The meaningful magnitudes are ratios. Being over 60 rather than under 40 raises your probability of experiencing at least 180 hours per year of uncompensable heat by roughly 13-fold at 1.5 degrees C of warming, using this paper’s own numbers. Put differently, over-60s make up about a fifth of the adult population but 78.5 percent of everyone exposed at 1.5 degrees C, a 3.7-fold over-representation. Going from 1 to 4 degrees C of warming takes global exposure from 2.3 percent to 35.6 percent of adults, a 15.5-fold relative increase and a 33 percentage point absolute increase.

What follows practically. First, thermoregulatory capacity is a modifiable aging biomarker, and the authors cite evidence that lifelong regular physical activity attenuates its decline. Aerobic fitness and heat acclimation training measurably raise sweat rate and plasma volume. Second, most heat deaths in older adults happen indoors, so reliable cooling is a longevity intervention, not a comfort purchase. Third, if you are over 60 and take beta blockers, diuretics or anticholinergics, your personal threshold is lower than the one modelled here. Fourth, location is a longevity variable with a quantifiable slope.

Context and Source

  • Open Access Paper: Exceeding human heat tolerance in a warming, ageing world: a global projection modelling study.
  • Institutions: Stanford University School of Medicine and Woods Institute for the Environment (lead); University of Nebraska Omaha; Pennsylvania State University Noll Laboratory, Department of Kinesiology; Purdue University; Texas Health Presbyterian Hospital Dallas; UT Southwestern Medical Center; University of Georgia.
  • Country: United States.
  • Journal: The Lancet Planetary Health, 2026.
  • Funding: US NIH, NSF, NASA, Yale Institute for Biospheric Studies, The Rockefeller Foundation.
  • Impact evaluation: The journal reported a Journal Impact Factor of 24.1 and a CiteScore of 28.4 in its most recent self-reported metrics, with more recent third-party estimates in the 20 to 21 range as the journal’s citation base matures. The impact score of this journal is approximately 20 to 24, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

Elastin
Elastin2752×1536 385 KB

Elastin is the rubber-band protein that lets your aorta recoil with every heartbeat, your lungs spring back with every breath, and your skin snap back when pinched. You make almost all of it before you finish growing, and you never meaningfully replace it. Over decades of mechanical fatigue, sunlight, and enzyme attack, it shatters into short peptides that leak into the bloodstream. This review argues that those fragments are not passive debris but active hormone-like signals that switch on immune cells and drive chronic, body-wide inflammation. The author, a dermatology researcher at the University of Michigan, sets out to answer a specific question: which organs are actually producing this circulating debris? His answer is that three tissues dominate, the aorta, the lungs, and the sun-damaged dermis, each with its own signature set of protein-cutting enzymes. The practical payoff he proposes is source-resolved biomarkers, meaning a future blood test that could tell a clinician whether a given patient’s inflammation is coming mainly from their arteries, their lungs, or their skin, and therefore which tissue to treat.

There is a protein in your body that is almost as old as you are. Elastin, the elastic fibre that gives arteries their recoil and lungs their spring, is laid down in the womb and in early childhood and then, for practical purposes, never renewed. By the time you are fifty, the elastin in your aorta is fifty years old and has been stretched roughly two billion times.

That longevity is the problem. A new mini-review from Taihao Quan at the University of Michigan pulls together an emerging and genuinely provocative idea: as elastin finally fatigues and fractures, the pieces it sheds are not inert rubbish. They are signalling molecules. One short sequence in particular, a six-amino-acid motif written VGVAPG, docks onto a receptor complex on the surface of monocytes and macrophages and tells them to start producing inflammatory cytokines. The result is inflammaging, the smouldering low-grade inflammation that tracks almost every disease of later life.

The evidence that pushed this from curiosity to serious hypothesis came in 2025, when a team led by Yi and colleagues injected these fragments into young mice at concentrations matching those found in elderly humans. The young animals put on fat, developed fatty livers, lost muscle, performed worse on treadmills, and died sooner. Blocking the receptor’s key enzyme, an enzyme called NEU1, did the reverse: median lifespan rose by around 17 per cent in males.

Quan’s contribution is to ask a question that sounds pedantic but is not. If these fragments matter, where are they coming from? Elastin, unlike collagen, is not everywhere. It is concentrated in exactly three places that take a beating: the aorta and large arteries, where it makes up 30 to 50 per cent of the vessel wall’s dry weight; the lung, whose alveoli inflate and deflate about 15,000 times a day in a bath of inhaled oxidants; and the dermis, which absorbs a lifetime of ultraviolet radiation. Each of these tissues degrades its elastin using a slightly different mix of enzymes.

The implication is a shift in how we might think about anti-inflammatory medicine. Rather than blanket immunosuppression, you could read the precise chemical signature of a patient’s circulating fragments, identify which organ is the dominant source, and intervene there. Someone whose fragments carry the fingerprint of macrophage elastase is telling you about their lungs. Someone whose fragments look neutrophil-cut may be telling you about sun-damaged skin.

That test does not exist yet. Neither does a usable drug. But the framing is new, and it is testable.

Actionable Insights

Be clear about what this review can and cannot do for you. It is a hypothesis paper with no human intervention data, so there is no supplement, dose, or protocol to take away from it. What it offers is a mechanistic reason to take three unglamorous behaviours more seriously, plus one number.

The number is this: in mice, blocking the receptor enzyme NEU1 with a compound called DANA raised median lifespan by 17.4 per cent in males and 12.2 per cent in females. Reconstructing the strength of that result from the reported statistics, a treated mouse was roughly a third as likely to die at any given moment as an untreated one. That is a large effect by animal-study standards, large enough that it should be treated with suspicion until someone repeats it. DANA is not a drug you can obtain, and nothing equivalent has been tested in a person.

The behaviours the mechanism supports are sun protection, not smoking, and blood pressure control. Each reduces the mechanical or chemical load on one of the three elastin reservoirs. None has a measured effect on circulating elastin fragments in humans.

Context and Source

  • Paywalled Paper: Circulating elastin fragments drive systemic aging: Where do pro-aging elastin fragments come from? A mini-review
  • Author: Taihao Quan, sole author
  • Institution: Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan
  • Country: United States
  • Journal: Mechanisms of Ageing and Development, volume 233 (2026), article 112218, published by Elsevier
  • Impact evaluation: The impact score of this journal is 6.5 (Journal Impact Factor, Web of Science, most recent release), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

CatStudy
CatStudy1920×1072 316 KB

A small randomized, double-blind, placebo-controlled trial reports that PURR-001, a once-weekly oral capsule combining a low-dose rapamycin analog, mirtazapine, and acarbose, produced a larger gain in body mass and back-muscle thickness than placebo in elderly sarcopenic cats over 12 weeks. Treated cats gained about 7.4 percent body mass versus 1.1 percent on placebo, and their epaxial (spinal) muscle height rose about 22.8 percent versus 9.0 percent. Blood safety markers stayed stable.

Muscle wasting in old age is one of the most reliable signatures of biological aging, and it is not unique to humans. Cats lose muscle too, and until now no drug had been formally tested against the age-related version of that decline, known as sarcopenia. A team backed by a Delaware-registered startup called The Cat Health Company, working with veterinary clinics in Romania and chemists at Politehnica Bucharest, set out to change that with a candidate they call PURR-001.

The big idea is deliberately unglamorous. Rather than betting on a single miracle molecule, the researchers built a combination pill that pokes at three connected levers of mammalian aging at once: nutrient sensing, low-grade chronic activation of the growth pathway mTOR, and subclinical insulin resistance. The active ingredients are a low dose of a rapamycin-like mTOR inhibitor, the appetite stimulant mirtazapine, and the blood-sugar drug acarbose. Two of these, rapamycin and acarbose, are the same pairing that has produced some of the largest lifespan extensions on record in the US National Institute on Aging’s mouse testing program, which is almost certainly why they appear here together.

Thirty-five elderly cats were randomly assigned to the drug or a matching placebo, and neither owners nor assessing vets knew which was which. Twelve weeks later, the cats on PURR-001 had gained noticeably more weight and, in a smaller subgroup scanned by ultrasound, thicker back muscles. The two measures tracked together, which is what you would hope to see if real muscle, not just fat, was being added. Routine blood work showed no sign of organ toxicity.

There are important caveats. Only 27 cats finished, the muscle-scan group was just 15 animals, and the study never tested whether the three-drug cocktail beats any single ingredient. A blood gene-expression readout meant to reveal the drug’s mechanism found essentially nothing. One treated cat died of severe pancreatitis, judged unrelated by the vets. Still, as a first controlled demonstration that feline age-related muscle loss is pharmacologically movable, it is a genuine opening rather than a conclusion.

Insights

The honest first message is that this is a cat study, and nothing here has been shown to work in humans. What it offers is a directional signal about a strategy that longevity researchers already find promising.

To see how big the reported effect actually is, effect size is the useful lens. Effect size asks not just whether a difference is real, but how large it is relative to the natural spread between individuals. A common yardstick is Cohen’s d, where roughly 0.2 is small, 0.5 is medium, and 0.8 or above is large. For body mass gain, the gap between drug and placebo works out to a Cohen’s d of about 0.95, a large effect. For back-muscle thickness it is even larger, roughly 1.4 to 1.5, though that came from only 15 cats so the true number is uncertain.

In plain terms, a typical 3.5 kg elderly cat on the drug gained roughly a quarter of a kilogram, versus almost nothing on placebo. The take-home for people is conceptual; combining several modest interventions that each nudge a different aging pathway may beat searching for one blockbuster, and preserving muscle is worth prioritizing as any mammal ages.

Context and Source

Leitura Relacionada: